Introduction:

Epigenetic research involves examining the mitotically heritable processes that regulate gene expression, independent of changes in the DNA sequence. Recent technical advances such as whole-genome bisulfite sequencing and affordable epigenomic array-based technologies, allow researchers to measure epigenetic profiles of large cohorts at a genome-wide level, generating comprehensive high-dimensional datasets that may contain important information for disease development and treatment opportunities.

Whole Genome Bisulfite Sequencing (WGBS) is used for detecting methylated cytosines by treating the DNA with sodium bisulfite before sequencing. WGBS is currently considered as the gold standard for studying genome-wide methylation at single base resolution. Methylome analysis is a valuable way to do a range of researches, including studies on gene regulation, cell differentiation, aging, tumorigenesis and phenotypic diversity.

In a NGS seqeuncing project, particular Methyl-Seq, it is very common to fall into the situation of being lack of enough materials for sequencing. Samples that are collected for deep study, such as NGS sequencing, are usually precious with very limited amount available. Sometimes, you have enough materials to start with, however, after several rounds of library preparations, you still can not get NGS datasets with desired quality, and now only very few samples are left for further test. It is the time to contact Complete Omics and learn more about our MyGene™-UltimateSens™ NGS technology, a NGS library construction method WITHOUT EXCESSIVE PCR AMPLIFICATION.

Sample types we accept:

1, Purified DNA samples

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

4, FFPE slide/ FFPE extract

5, Fossil

6, Customized sample types (please contact us to discuss)

Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell

June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of…

Read more

Complete Omics Makes Landmark Debut at ASMS 2025

June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.

Read more

Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing

Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This…

Read more

Some of our impacts